Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | COVID-19: treating CLL patients

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the management of chronic lymphocytic leukemia (CLL) patients during the COVID-19 pandemic. Specifically, Dr Tam debates the use of BTK inhibitors in patients positive for SARS‐CoV‐2. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).